TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29266392

Group type: EXPERIMENTAL
Intervention: 60-µs pulse width
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10- to 50-µs pulse widths
Number of subjects: 10
Study: 28717347

Group type: EXPERIMENTAL
Intervention: Fish oil group (n=10) consuming eight 300-mg EPA-rich fish oil softgel capsules per day for 8 weeks and continued for 5 days after exercise.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n=11) consuming an equivalent number of placebo capsules.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fish oil group (n=10)
Number of subjects: 21
Study: 26179767

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily after initial heparin treatment
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Warfarin (control group)
Number of subjects: 1109
Study: 24174925

Group type: EXPERIMENTAL
Intervention: Client-centered global stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cognitive training (of working memory)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 21225890

Group type: EXPERIMENTAL
Intervention: Inhomogeneous static magnetic field (SMF) exposure for 30 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: SHAM exposure
Number of subjects: 15
Study: 18318674

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid treatment (experimental group)
Number of subjects: 163

Group type: COMPARATOR
Intervention: No antenatal corticosteroid treatment (control group)
Number of subjects: 163
Study: 16898074

Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium tablet formulation THYROHORMONE/Ni‐The Ltd (0.2 mg/tab)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference oral solution (0.3 mg/100 ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 14634544

Group type: COMPARATOR
Intervention: Transdermal 17beta-estradiol (E(2)) 50 microg
Number of subjects: 152

Group type: COMPARATOR
Intervention: Oral E(2) 1 mg
Number of subjects: 152

Group type: COMPARATOR
Intervention: Oral E(2) 1 mg + gestodene 25 microg
Number of subjects: 152
Study: 10847209

Group type: EXPERIMENTAL
Intervention: Inactivated, subunit trivalent influenza vaccine (one dose: 2027 subjects, two doses: 8712 subjects)
Number of subjects: 22762

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 22762
Study: 8889680

Group type: EXPERIMENTAL
Intervention: MDMA, single oral dose of 1.5 mg/kg body weight
Number of subjects: 2
Study: 1894861

Group type: EXPERIMENTAL
Intervention: Continuous intravenous diltiazem infusion (10 to 15 mg/h)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined diltiazem infusion (double-blind and open label)
Number of subjects: 47
Study: 7201833

Group type: EXPERIMENTAL
Intervention: Propafenone (Rytmonorm), 900 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Disopyramide, 600 mg daily
Number of subjects: 12
Study: 31407311

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment (weekly or every 2 weeks)
Number of subjects: 2116

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2116
Study: 30706864

Group type: EXPERIMENTAL
Intervention: Video Projected Practical Examination (VPPE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Practical Examination
Number of subjects: 0
Study: 29171358

Group type: EXPERIMENTAL
Intervention: Xtampza ER (intact or crushed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OxyContin (intact or crushed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release (IR) oxycodone (crushed)
Number of subjects: 0
Study: 26009945

Group type: EXPERIMENTAL
Intervention: 10-min exercise break
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 20-min exercise break
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sedentary condition (10 min)
Number of subjects: 96
Study: 23223108

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 42
Study: 21471843

Group type: EXPERIMENTAL
Intervention: Seex retractor system (SRS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional Cloward-style retractor (CRS)
Number of subjects: 26
Study: 19417885

Group type: EXPERIMENTAL
Intervention: povidone‐iodine/fluoride foam (n = 30, experimental group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo fluoride foam (n = 31, control group)
Number of subjects: 61
Study: 17005043

Group type: EXPERIMENTAL
Intervention: Adalimumab (two doses, subcutaneously administered)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 15123024

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 0
Study: 11191937

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Slow release metoprolol
Number of subjects: 127
Study: 8025209

Group type: EXPERIMENTAL
Intervention: Preventive therapies for insulin-dependent diabetes (specific therapies not detailed)
Number of subjects: 0
Study: 3789332

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Cladosporium herbarum
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30287711

Group type: EXPERIMENTAL
Intervention: SonicFill Bulk Fill composite
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tetric EvoCeram Bulk Fill composite
Number of subjects: 20
Study: 27660194

Group type: EXPERIMENTAL
Intervention: Sertraline plus structured, tailored group physical exercise (S + EX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline alone (S)
Number of subjects: 0
Study: 24735707

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) combined with enhanced community services (ECS)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Enhanced community services (ECS) alone
Number of subjects: 600
Study: 22947426

Group type: EXPERIMENTAL
Intervention: Maribavir (100 mg twice daily)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Ganciclovir (1000 mg three times daily)
Number of subjects: 303
Study: 20087154

Group type: COMPARATOR
Intervention: Abacavir (ABC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) + Tenofovir disoproxil fumarate (TDF) dual-therapy
Number of subjects: 21
Study: 18207225

Group type: EXPERIMENTAL
Intervention: Rivastigmine 1.5 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methamphetamine (3 mg, IV)
Number of subjects: 22
Study: 15998547

Group type: EXPERIMENTAL
Intervention: Decubitus direct current treatment (DDCT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 63
Study: 12571204

Group type: COMPARATOR
Intervention: (123)I‐5‐I‐R91150
Number of subjects: 15
Study: 10574383

Group type: EXPERIMENTAL
Intervention: Gap pursuit tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-gap tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gap tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8818375

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy administered by competent therapists (n = 30)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive-behavior therapy administered by therapists of uncertain competence (n = 40)
Number of subjects: 70
Study: 1549648

Group type: EXPERIMENTAL
Intervention: Placebo with expectancy of enhanced performance (E(+))
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Placebo with expectancy of impairment (E(-))
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Placebo with no information (E(?))
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (E(0))
Number of subjects: 56
Study: 4015285

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oxprenolol 160 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Metoprolol 200 mg
Number of subjects: 150
Study: 31614532

Group type: EXPERIMENTAL
Intervention: Mung bean protein supplementation (18 g/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no protein supplementation)
Number of subjects: 37
Study: 30024639

Group type: EXPERIMENTAL
Intervention: AIBD plus treatment as usual (TAU)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 72
Study: 27281561

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CTC analysis at progression
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High levels of cfDNA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High levels of CTCs
Number of subjects: 60
Study: 24140730

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 556
Study: 22564837

Group type: EXPERIMENTAL
Intervention: Clarithromycin administered intravenously for 3 days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 200
Study: 20587580

Group type: EXPERIMENTAL
Intervention: rs806381 polymorphism
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: rs1049353 polymorphism
Number of subjects: 783

Group type: COMPARATOR
Intervention: None of the SNPs analysed
Number of subjects: 783
Study: 19031133

Group type: EXPERIMENTAL
Intervention: Fast track programs (FT); 44 cases
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group; 39 cases
Number of subjects: 83
Study: 15794443

Group type: EXPERIMENTAL
Intervention: Automated pupillometer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual examination with a penlight or similar light source
Number of subjects: 20
Study: 12214831

Group type: EXPERIMENTAL
Intervention: Loading dose of magnesium sulfate
Number of subjects: 401

Group type: COMPARATOR
Intervention: Standard regime of magnesium sulfate
Number of subjects: 401
Study: 10325275

Group type: EXPERIMENTAL
Intervention: Natural cycles (n = 16)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Stimulated cycles (n = 25)
Number of subjects: 11
Study: 8960845

Group type: EXPERIMENTAL
Intervention: Diet control of NIDDM
Number of subjects: 1139
Study: 1729588

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation advising physicians on treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: First-generation antidepressants (amitriptyline, imipramine, doxepin)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Newer antidepressants (nortriptyline, desipramine, trazodone, fluoxetine)
Number of subjects: 119
Study: 6431572

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine, sublingually
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium cromoglycate by inhalation
Number of subjects: 8
Study: 30781691

Group type: EXPERIMENTAL
Intervention: Health education post
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Risk communication post
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Post in the afternoon
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Post in the evening
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Video format
Number of subjects: 2123
Study: 29482422

Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 27323615

Group type: EXPERIMENTAL
Intervention: Ligustrazine (2 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 25074865

Group type: EXPERIMENTAL
Intervention: Finasteride 0.25% topical solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Finasteride 1 mg tablet
Number of subjects: 24
Study: 22198445

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 106
Study: 20339154

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with pravastatin (40 mg once daily)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Antihypertensive treatment without pravastatin
Number of subjects: 508
Study: 17010609

Group type: EXPERIMENTAL
Intervention: HER-2 gene expression
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TOPO IIalpha and MAPT gene expression
Number of subjects: 50
Study: 16137586

Group type: EXPERIMENTAL
Intervention: Nonenhanced CT within 48 hours of admission
Number of subjects: 697

Group type: COMPARATOR
Intervention: Nonenhanced CT over the subsequent 6 days
Number of subjects: 697
Study: 11961331

Group type: EXPERIMENTAL
Intervention: AmF-SnF2 mouthrinse (Meridol with and without 5% alcohol)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (CHX)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 5
Study: 11329096

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Piroxicam 20 mg orally in the morning and placebo in the evening
Number of subjects: 49
Study: 7553230

Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta), retinoids (R), and tamoxifen (TAM)
Number of subjects: 49
Study: 2258364

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 11
Study: 7041752

Group type: EXPERIMENTAL
Intervention: Regular endolymphatic shunt
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham (placebo) operation (regular mastoidectomy)
Number of subjects: 30
Study: 31210498

Group type: EXPERIMENTAL
Intervention: Nursing intervention including two education sessions and five telephone calls over two months
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 136
Study: 29101171

Group type: EXPERIMENTAL
Intervention: HIIE 4 × 4
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HIIE 16 × 1
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 27599329

Group type: EXPERIMENTAL
Intervention: Bevacizumab 1% (4 mg/d)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Estriol 0.1% (0.4 mg/d)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10% (40 mg/d)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 121
Study: 25058146

Group type: EXPERIMENTAL
Intervention: Low-salt diet (3.0 g/day of NaCl) for 7 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-salt diet (18.0 g/day of NaCl) for 7 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-salt diet with potassium supplementation (18.0 g/day of NaCl + 4.5 g/day of KCl) for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: All dietary interventions
Number of subjects: 42
Study: 22297625

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg IV plus haloperidol 2 mg IM (group DH)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg IV plus ondansetron 4 mg IV (group DO)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Dexamethasone 5 mg IV (group D)
Number of subjects: 135
Study: 21175313

Group type: EXPERIMENTAL
Intervention: Imatinib plus peginterferon alfa-2a (90 μg weekly)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Imatinib (400 mg daily) alone
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg daily)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg daily) plus cytarabine (20 mg/m² daily on days 15-28)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Imatinib plus peginterferon alfa-2a
Number of subjects: 636
Study: 17704091

Group type: EXPERIMENTAL
Intervention: Narcotrend-controlled propofol/remifentanil anaesthetic regimen
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 48
Study: 15925768

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Haemetaporphyrin derivative (HpD) after surgical resection
Number of subjects: 136
Study: 12488409

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² intravenously on days 1 to 5, every 28 days)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CVP (cyclophosphamide 750 mg/m² and vincristine 1.2 mg/m² intravenously on day 1, prednisone 40 mg/m² orally on days 1 to 5, every 21 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m²)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CVP
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 91
Study: 9577932

Group type: EXPERIMENTAL
Intervention: Ky5-exposed workers
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonexposed workers
Number of subjects: 57
Study: 8587758

Group type: EXPERIMENTAL
Intervention: 500 ml of 5% glucose water containing 4 g of regular instant coffee
Number of subjects: 93

Group type: COMPARATOR
Intervention: Baseline: 500 ml of 5% glucose water
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Duplicate coffee measurements
Number of subjects: 93
Study: 2632448

Group type: EXPERIMENTAL
Intervention: Topical sulindac therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 0
Study: 592986

Group type: EXPERIMENTAL
Intervention: Bed bicycle with elevated legs and elastic stockings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard method, usually walking)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor cycle exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 31315962

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28657601

Group type: EXPERIMENTAL
Intervention: Alcoholic wine (AW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spirits (S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcoholic beer (AB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-alcoholic wine (NAW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 0
Study: 26237828

Group type: EXPERIMENTAL
Intervention: WCR plus TCM (insulin, isoniazid, rifampicin, pyrazinamide, ethambutol + Qi‐boosting and Yin‐nourishing decoction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: WCR (insulin, isoniazid, rifampicin, pyrazinamide, ethambutol)
Number of subjects: 60
Study: 23483023

Group type: EXPERIMENTAL
Intervention: Ensure preparation
Number of subjects: 198

Group type: COMPARATOR
Intervention: PEG preparation
Number of subjects: 198
Study: 21683993

Group type: EXPERIMENTAL
Intervention: Minimal disease (MD)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Abdominal peritoneal disease (APD)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Upper abdominal disease (UAD)
Number of subjects: 417

Group type: COMPARATOR
Intervention: MD + APD (combined)
Number of subjects: 417
Study: 19454924

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 52

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 52
Study: 16674760

Group type: EXPERIMENTAL
Intervention: Semi-standardized acupuncture
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 28
Study: 15355454

Group type: COMPARATOR
Intervention: Fixed 10‐mg HC dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weight‐adjusted dosing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Food taken before HC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Serum cortisol measured 4 h after HC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: New thrice‐daily treatment regimen
Number of subjects: 20
Study: 11318241

Group type: EXPERIMENTAL
Intervention: 7-session small-group cognitive-behavioral HIV risk reduction intervention
Number of subjects: 189

Group type: COMPARATOR
Intervention: Time-matched comparison intervention
Number of subjects: 189
Study: 9408337

Group type: EXPERIMENTAL
Intervention: Shouldice operation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Bassini-Kirschner operation
Number of subjects: 129
Study: 7508321

Group type: EXPERIMENTAL
Intervention: Photocoagulation intervention (specific details not provided in the abstract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided in the abstract)
Number of subjects: 0
Study: 3310200

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg in the evening
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 31916142

Group type: EXPERIMENTAL
Intervention: High Physical and Sexual Violence and Injuries
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: High Physical and Low Sexual Violence and Injuries
Number of subjects: 659

Group type: COMPARATOR
Intervention: Low Physical and Sexual Violence
Number of subjects: 659
Study: 28479016

Group type: EXPERIMENTAL
Intervention: Rapid weight loss (4 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gradual weight loss (8 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups after weight stabilization
Number of subjects: 35
Study: 26914668

Group type: EXPERIMENTAL
Intervention: Thoracoscopic pulmonary vein isolation and atrial appendage ligation (TPVIAL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 23
Study: 25073881

Group type: EXPERIMENTAL
Intervention: Experimental nursing intervention to help family caregivers manage post-cardiac surgery delirium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 30
Study: 24373585

Group type: EXPERIMENTAL
Intervention: High-efficiency particle air filter
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no air filtration)
Number of subjects: 48
Study: 20023437

Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 650

Group type: COMPARATOR
Intervention: nevirapine
Number of subjects: 650
Study: 18593799

Group type: EXPERIMENTAL
Intervention: High-intensity walking (75% of VO2peak)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking (50% of VO2peak)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-intensity walking (25% of VO2peak)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All walking intensities
Number of subjects: 14